SMSPHARMA2023-04-012023-06-30 SMSPHARMA2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member SMSPHARMA2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member SMSPHARMA2023-06-30 SMSPHARMA2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532815 SMSPHARMA NOTLISTED SMS Pharmaceuticals Limited Equity 2023-04-01 2024-03-31 2023-08-08 2023-08-01 INR Lakhs First quarter 11:00:00 13:25:00 2023-08-08 2023-08-08 Not applicable Single segment Bulk Drugs 2023-04-01 2023-06-30 Unaudited Consolidated 1353394000.00 5129000.00 1358523000.00 917215000.00 0.00 -172228000.00 135540000.00 63227000.00 76912000.00 211030000.00 1231696000.00 126827000.00 0.00 126827000.00 34000000.00 4739000.00 38739000.00 0.00 88088000.00 0.00 0.00 0.00 5328000.00 93416000.00 -464000.00 92952000.00 0.00 0.00 0.00 84652000.00 1 1.10 1.10 0.00 0.00 1.10 1.10 1 The above unaudited consolidated financial results have been reviewed by the Audit Committee on August 7,2023 and has been approved by the Board of Directors at its meeting held on August 08,2023. The Statutory auditors of the company have carried out a limited review on the consolidated financial results and expressed an unmodified conclusion thereon. 2 These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ( Ind AS ) prescribed under section 133 of the Companies Act,2013 ( the Act ) read with relevant rules issued thereunder('INDAS) and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI). 3 VKT Pharma Private Limited is considered as an Associate Company for the consolidation in which the Company holds 36.55% as on March 31, 2023 in their equity. Accordingly, the results include appropriate share of the results of said Associate . The Company has another Joint venture Chemo SMS Enterprises SL in which there were no operations during the reporting period. 4 Consolidated Financial Statements have been prepared by applying Accounting Standard Ind AS 27 Accounting for Investments in Associates in Consolidated Financial Statements as applicable under the Companies Act,2013 and applicable rules there under. 5 The Group is engaged in the manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108. 6 The figures for the quarter ended March 31, 2023 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2023 and published year to date figures up to third quarter of the financial year ended March 31, 2023. The figures have been regrouped/reclassified as necessary. manufacturing expenses 133798000.00 other expenses 77232000.00 Other comprehensive income [Abstract] -464000.00 -464000.00 0.00 0.00